The company has predicted that Imaavy — now approved for generalized myasthenia gravis — could eventually earn more than $5 ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s ...

Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more ...

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

The delay for Stealth Biotherapeutics comes amid a heightened focus on the impact FDA job cuts might have on drug reviews.

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...